These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-001959-11 Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled intern... 2008-07-28 due-trials
Reported results 2004-001960-30 Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradina compared to placebo on top of a background therapy with atenolol in patients with stable angina pectoris. A 4-mo... 2007-10-17 due-trials
Reported results 2004-002577-23 Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for 12 weeks in out-patients with Generalised Anxiety Disorder. A randomised flexible dose double-... 2006-01-09 due-trials
Completed, but no date, and reported results 2004-002707-32 HEMODEX study- Detralex* versus placebo in the treatment of acute hemorrhoids in patients with acute hemorrhoidal attack. One week, double-blind, randomized, placebo controlled, multicentre study. bad-data
Completed, but no date, and reported results 2004-003955-37 Efficacy of perindopril/indapamide combination on coronary Pet Scan parameters. A 6 month, open non controlled stydy in hypertensive patients bad-data
Reported results 2004-003981-13 A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder. A 8 to 10 weeks open period treatment with agomelat... 2007-07-11 due-trials
Reported results 2004-004008-19 EFFICACY AND SAFETY OF AGOMELATINE (25 MG/DAY WITH POTENTIAL ADJUSTMENT TO 50 MG) GIVEN ORALLY FOR 8 WEEKS IN OUT-PATIENTS WITH SEVERE MAJOR DEPRESSIVE DISORDER. A RANDOMISED DOUBLE-BLIND, PARALLEL G... 2008-03-14 due-trials
Reported results 2004-004009-10 Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity circadian rhythms in outpatients with Major Depressive Disorder. A randomized, double-blind interna... 2007-03-12 due-trials
Reported results 2004-004327-35 Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period. An international multicentre, 3 parallel groups,... 2006-03-29 due-trials
Reported results 2005-000016-27 Safety an efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms: A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-group, ... 2006-10-17 due-trials
Completed, but no date, and reported results 2005-000077-22 Acceptability, safety, pharmacokinetics and effects on blood pressure of a daily dose of 0.025 to 0.135 milligram per kilogram of S 90652, a paediatric formulation of perindopril, in 2-16 years old hy... bad-data
Reported results 2005-000103-34 Evaluation of the effects of 3 succesive oral dosages (2.5; 5; 7.5 mg b.i.d.) of ivabradine in patients with stable moderate to severe systolic chronic heart failure treated with beta-blockers A 9 we... 2007-01-31 due-trials
Reported results 2005-000314-12 Effect of 3 doses ( 20, 40 and 60 mg) of a sublingual formulation of piribedil ( S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson's disease patients after a 14 d... 2007-07-17 due-trials
Reported results 2005-000474-42 Safety and effects on blood pressure of a daily dose of 0.025 to 0.135 milligram per kilogram of S 90652, a paediatric formulation of perindopril, in hypertensive children having received S 90652 - an... 2010-04-27 due-trials
Completed, but no date, and reported results 2005-002010-38 Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Dise... bad-data
Reported results 2005-002388-95 EFFICACY OF AGOMELATINE 25 TO 50 MG/DAY GIVEN ORALLY ON QUALITY OF REMISSION IN ELDERLY DEPRESSED PATIENTS, AFTER A 12-WEEK TREATMENT PERIOD. A RANDOMISED, DOUBLE-BLIND, FLEXIBLE-DOSE INTERNATIONAL... 2008-01-21 due-trials
Reported results 2005-002494-75 The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 2 years in the treatment of knee osteoarthritis. A prospective multicentre, intern... 2011-02-17 due-trials
Completed, but no date, and reported results 2005-003281-41 A factorial randomised trial of blood pressure lowering with a fixed low-dose perindopril-indapamide combination and intensive glucose control with a modified-release gliclazide-based regimen for the ... bad-data
Reported results 2005-003700-10 Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack. The PERFORM Study. An internat... 2011-03-30 due-trials
Reported results 2005-004798-60 A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex (150 mg od to 150 mg tid) versus pioglitazone (30 mg od to 45 mg od) in combination with sulfonylure... 2009-01-15 due-trials
Reported results 2005-004881-17 Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major depr... 2008-12-22 due-trials
Completed, but no date, and reported results 2005-004986-41 PRotelos 2g in the OSteoporosis treatment, the Tolerability and Efficacy Profile bad-data
Reported results 2005-005122-31 Evaluation of the effects on heart rate, haemodynamic parameters, safety and tolerability of 5 mg bolus of ivabradine followed by 8-hour infusion at the dose of 5 mg of ivabradine given after a percut... 2009-04-20 due-trials
Reported results 2006-000708-18 Effects of Ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double blind placebo contr... 2010-04-19 due-trials
Reported results 2006-001240-30 Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os) and rosiglitazone (4 to 8 mg daily per os) given in combination with metformin in type 2 diabetic patients. A 2-year inte... 2008-03-12 due-trials
Reported results 2006-002732-22 A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2g per day of strontium ranelate versus alendronate 70mg per week in women with postme... 2009-02-26 due-trials
Completed, but no date, and reported results 2006-004194-10 Long-term effects of strontium ranelate on knee osteoarthritis symptoms. A 2-year prospective, randomised, placebo-controlled study. bad-data
Reported results 2006-004716-48 Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder. A 6-week randomised, double-blind parallel groups study versus com... 2008-10-16 due-trials
Reported results Terminated 2006-004717-17 The efficacy and safety of 2g strontium ranelate in the treatment of osteoporosis in men. A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of... 2007-09-26 due-trials
Reported results 2006-005475-17 Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to pat... 2015-02-12 due-trials
Reported results 2006-005581-39 A double blind, multicenter, international randomised study to assess the effects of 6 months or 12 months administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week on bone... 2010-02-11 due-trials
Reported results 2006-005674-47 Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an ope... 2009-09-29 due-trials
Reported results 2006-005721-28 EDET study - Efficacy of Detralex® in Edema Treatment. An open, 6-month, multicentre study. 2008-04-08 due-trials
Reported results 2006-005797-44 Efficacy and safety of the fixed oral low-dose perindopril arginine 3.5 mg/amlodipine 2.5 mg combination compared with each component (perindopril arginine 3.5 mg and amlodipine 2.5 mg) and with perin... 2008-12-30 due-trials
Reported results 2006-005799-42 Perindopril Amlodipine Regimen versus AT1-Receptor Blocker/thiazide: a comparison of Blood pressure Lowering: Efficacy and Safety. A randomised, double blind, 9 month study of the efficacy and safety ... 2009-08-13 due-trials
Reported results 2006-005886-21 Evaluation des effets de l’ivabradine 5 mg et 7.5 mg en 2 prises par jour par voie orale chez des patients insuffisants cardiaques avec une hypertension artérielle insuffisamment équilibrée par Perind... 2009-05-07 due-trials
Reported results 2006-006086-16 The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis. A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 ... 2011-03-04 due-trials
Reported results 2006-006184-23 A randomised, double-blind, placebo- and olanzapine- controlled, parallel-group study to evaluate the efficacy and safety of 3 fixed doses of S 33138 in treatment of patients with an acute episode of ... 2010-04-18 due-trials
Reported results 2006-006246-34 Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with a calcium antagonist (amlodipine or nifedipine) in patie... 2012-09-04 due-trials
Reported results 2006-006540-54 Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multicentr... 2008-09-06 due-trials
Reported results 2006-006754-10 Efficacy and safety of gliclazide MR (30 to 120 mg per day) associated or not to metformine or to an α-glucosidase inhibitor during the fast of the Ramadan in type 2 diabetic patients. A 5 to 8 months... 2008-05-13 due-trials
Reported results 2007-000176-17 Effects of terutroban versus aspirin on composition of atherosclerotic plaque in patients undergoing a carotid endarterectomy.A multicentre, randomised, double blind, two parallel group study comparin... 2009-04-20 due-trials
Reported results 2007-001509-11 A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week in women with post... 2011-04-07 due-trials
Reported results 2007-003312-65 Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, internatio... 2009-04-24 due-trials
Reported results 2007-003808-35 Dose ranging study of S 44497 administered orally once daily for four weeks in type 2 diabetic patients. A multicentre, randomised, double-blind, double-dummy, phase II study versus placebo and glimep... 2009-04-28 due-trials
Reported results 2007-005564-27 Effect of agomelatine (25 mg) given orally once a day for 7 days on cerebral activity measured by functional MRI during processing of emotional stimuli in patients with Major Depressive Disorder. A ra... 2011-10-19 due-trials
Reported results 2007-006793-28 Effects of a 10 or 15 mg single intravenous bolus of ivabradine versus placebo on heart rate control during a multislice computed tomography coronary angiography for the evaluation of coronary artery ... 2009-09-25 due-trials
Completed, but no date, and reported results Terminated 2007-007026-22 Assessment of the effects on 24-hour ambulatory blood pressure and the safety of a once-a-day oral 8 mg perindopril morning administration versus evening administration in hypertensive patients. An 8-... bad-data
Reported results 2008-001703-32 Primary hyperparathyroidism: does a systematic treatment improve the calcium- and bone metabolism after successful surgery? – Part Systematic treatment of osteopenic and osteoporotic postmenopausal p... 2014-12-31 due-trials
Reported results Terminated 2008-002647-16 Assessment of blood glucose profile in type 2 diabetic patients after a one-week treatment with gliclazide 60 mg MR using both the glycaemic Holter method and multiple blood glucose samples. A double-... 2009-03-17 due-trials
Completed, but no date, and reported results Terminated 2008-003421-17 Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double... bad-data
Reported results 2008-003856-32 Evaluation de l’effet de la prise orale de perindopril orodispersible à la dose de 0,150 mg/kg/jour sur la fonction musculaire et myocardique dans la dystrophie musculaire de Duchenne à un stade préco... 2011-10-19 due-trials
Reported results 2008-004642-92 Evaluación de la eficacia y el beneficio clínico de agomelatina (25 a 50 mg/día) durante un período de tratamiento de 6 meses en pacientes con Trastorno Depresivo Mayor.Estudio aleatorizado, doble cie... 2010-08-04 due-trials
Completed, but no date, and reported results Terminated 2008-005262-31 Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose aspirin and with elevated levels of thromboxane A2. A multicentre, randomised, double-blind, cross-over study co... bad-data
Reported results 2008-007670-37 Exploratory study of S 38093 versus placebo in patients with mild to moderate Alzheimer’s Disease. An international, multi-centre, randomised, double-blind, placebo-controlled phase IIa study. 2010-09-13 due-trials
Reported results 2008-008220-32 Efficacité clinique de VALDOXAN dans les conditions de pratique quotidienne (efficience) chez des patients déprimés, en switch ou naïfs de traitement Etude clinique interventionelle de phase IV, mult... 2010-08-04 due-trials
Reported results 2009-010112-15 Effets cliniques de VALDOXAN® (25 ou 50mg) à long terme chez des patients déprimés - Etude clinique, nationale, interventionnelle de phase IV, multicentrique, réalisée en ouvert. Etude Valdoxan D - EX... 2010-10-13 due-trials
Reported results 2009-010642-57 “Efficacy and safety of ValdoxanR given orally once a day for 24 weeks in patients with Major Depressive Disorder.” Open, national, multicentric clinical trial for the evaluation of the antidepressant... 2010-09-01 due-trials
Reported results 2009-011238-84 Efficacy and safety of 3 dose regimens of agomelatine (10, 25, 25-50 mg) versus placebo given once a day for 6 weeks in out-patients suffering from moderate to severe Major Depressive Disorder. A 6-we... 2012-05-11 due-trials
Reported results 2009-011360-10 Efectos de ivabradina en pacientes con arteriopatía coronaria estable sin insuficiencia cardíaca clínica. Estudio multicéntrico, internacional, aleatorizado, doble ciego, controlado con placebo Study... 2014-01-24 due-trials
Reported results 2009-011558-16 Evaluación de los efectos de 4 dosis orales de S44121 versus placebo sobre la función cardiaca y el NT-proBNP en pacientes con insuficiencia cardiaca crónica y disfunción ventricular izquierda.Estudio... 2011-03-31 due-trials
Reported results 2009-011559-38 Evaluación de los efectos de 4 dosis orales de S44121 versus placebo sobre la función cardiaca y el NT-proBNP en pacientes con insuficiencia cardiaca crónica y disfunción ventricular izquierda no trat... 2012-12-28 due-trials
Reported results 2009-011560-11 Effects of three oral dosage of S 44121 on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1. A 3-days, single-blind, internation... 2011-01-21 due-trials
Reported results 2009-011795-29 Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomised, double-blind, flexible-dose, parallel group... 2011-10-07 due-trials
Reported results 2009-012035-15 Safety and efficacy of S 38093 and donepezil, during 4 weeks, in patients with mild to moderate Alzheimer's Disease. An international, multi-centre, randomised, double-blind, placebo controlled, phase... 2010-07-07 due-trials
Reported results 2009-012560-14 Réponse au VALDOXAN® et restauration des rythmes de vie dans la dépression unipolaire : Etude VALDOXAN® D-Rhythm. Etude clinique interventionnelle de phase IV, multicentrique 2010-09-07 due-trials
Exempt, with results 2009-013691-47 Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin’s Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia 2016-11-23 not-yet-due
Reported results 2009-013789-17 Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double... 2011-07-20 due-trials
Reported results 2009-013935-39 "Eficacia y seguridad de la administración oral diaria de S06911 (combinación fija de ranelato de estroncio 2g / vitamina D3 1000 UI) en la insuficiencia de vitamina D para el tratamiento de la osteop... 2011-07-01 due-trials
Reported results 2009-014045-92 Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomised, ... 2011-09-01 due-trials
Reported results 2009-014270-18 "Eficacia y seguridad de una administración oral diaria de S06911 (combinación fija de ranelato de estroncio 2g / vitamina D3 1000UI) en la deficiencia de vitamina D para el tratamiento de la osteopor... 2011-06-22 due-trials
Reported results 2009-014271-41 A multicenter, prospective, randomized, double-blind, placebo-controlled, international study to assess the effects of 2g per day of strontium ranelate versus placebo on the time to fracture healing i... 2012-03-21 due-trials
Completed, but no date, and reported results Terminated 2009-014810-87 Effect of Memantine 20 mg (Ebixa) and Donepezil 5 mg (Aricept) on motor cortex plasticity induced by paired associative stimulation using transcranial magnetic stimulation (TMS) in patients suffering ... bad-data
Reported results 2009-014940-12 "Evaluación de los efectos antiarritmicos de 3 dosis orales de S44121 versus placebo en pacientes con insuficiencia cardiaca crónica, disfunción ventricular izquierda sistólica y riesgo de presentar a... 2015-03-16 due-trials
Reported results 2009-016713-20 Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder. A randomised, double-bli... 2014-04-25 due-trials
Reported results 2009-017039-16 Effect of strontium ranelate (2g per day) in the management of long bone fractures with delayed-union or non union: an international open label study 2013-04-05 due-trials
Reported results 2009-018175-14 Effects of ivabradine IV versus placebo on haemodynamic parameters in patients with a low cardiac output syndrome following planned coronary artery bypass surgery and requiring positive inotropic trea... 2012-06-06 due-trials
Exempt, with results 2010-019121-34 An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics, and Pharmacodynamics of the dual VEGFR-FGFR Tyrosine Kinase Inh... not-yet-due
Reported results 2010-019556-44 Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive Disorder. A 3-week, randomised, double then single-blind, controlled, parallel groups... 2011-12-21 due-trials
Reported results 2010-020215-36 A prospective, controlled, double blind, international study to assess the effects of strontium ranelate vs. placebo on the reduction of periprosthetic bone loss in patients with total hip arthroplast... 2013-04-26 due-trials
Reported results 2010-020945-28 Perindopril arginine/Amlodipine versus Valsartan/Amlodipine antihypertensive strategies: Efficacy and safety in mild to moderate hypertensive patients. A randomised, double blind 6-month study follo... 2013-01-11 due-trials
Reported results 2010-021270-11 Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in patients operated on for varicose veins with conservation of the great saphenous vein. A multicentre, double blind... 2014-06-30 due-trials
Reported results 2010-022134-89 The efficAcy and safety of Trimetazidine in Patients with angina pectoris having been treated by percutaneous Coronary Intervention. ATPCI study An international, multicentre, randomised, double-blin... 2019-12-13 due-trials
Reported results 2010-023576-10 Early effect of agomelatine on general interest in outpatients with Major Depressive Disorder. A 12-week, randomized, double-blind, multicentre study with parallel groups: agomelatine (25mg/day given ... 2013-04-26 due-trials
Reported results 2010-024191-25 Effects of agomelatine (25 to 50 mg/day) on circadian rhythms in patients with Major Depressive Disorder. An exploratory 6-week open, flexible dose, international multicentre, non comparative study. 2014-07-25 due-trials
Reported results 2010-024626-37 Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo in patients with mild to moderate Alzheimer’s disease. A 24- week international, multi-centre, randomised, double-blind, p... 2014-03-21 due-trials
Reported results Terminated 2011-000579-15 Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1 ... 2013-10-18 due-trials
Reported results 2011-000708-17 A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteopo... 2014-06-26 due-trials
Reported results 2011-000783-98 Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise stress in patients with coronary artery disease and exercise inducible ischaemia. Effects of... 2014-08-13 due-trials
Reported results 2011-001283-22 International follow-up study, after the investigational drug exposure in diabetic patients previously included in the REGULATE trial (benfluorex versus pioglitazone). 2013-04-02 due-trials
Reported results 2011-001292-39 Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years. A rand... 2014-02-26 due-trials
Reported results Terminated 2011-002370-23 A double-blind, multicenter, international randomised study to assess the effects of 4 month-oral administration of 2g per day of strontium ranelate versus placebo on the bone quality and remodelling,... 2013-05-24 due-trials
Reported results 2011-003328-11 Patient pREference and satisFaction for pErindopril oRodispersible vs convENtional tablets in daily Clinical practicE PREFERENCE Étude clinique interventionnelle, menée en ouvert et en consultation de... 2014-04-28 due-trials
Reported results 2011-004046-18 Knee joint replacement over 5 years in patients with knee osteoarthritis. A long term follow up study in patients of the CL3-12911-018 study. Studio di follow up a lungo termine per pazienti che h... 2014-06-30 due-trials
Reported results Terminated 2011-004779-35 Effects of oral chronic administration of ivabradine (7.5 mg bid) in comparison to placebo (bid) on top of beta-blockers, on central aortic blood pressure. Randomized, cross-over, double blind, multic... 2014-05-13 due-trials
Reported results 2011-005320-17 Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from Major Depressive Disorder. An exploratory, randomised, double-blind, international, multicentre study ... 2014-10-03 due-trials
Reported results 2011-005862-40 Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer's Disease. A 24-week international, m... 2015-01-29 due-trials
Reported results 2011-006054-82 Efficacy and safety assessment of two schemes of oral administration of once-daily extended release metformin (metformin XR) in type 2 diabetic patients previously treated with metformin in combinatio... 2013-03-27 due-trials
Reported results Terminated 2012-000215-89 Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease and with impaired endothelial function An international, multicentre, randomised, doubl... 2014-04-18 due-trials
Reported results 2012-001125-27 A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet?s Disease uveitis Estudio controlado frente a placebo, aleatorizado, do... 2015-09-30 due-trials
Reported results 2012-001658-24 Efficacy and safety of fixed-dose combination Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg versus Perindopril 5 mg / Indapamide 1.25 mg single pill in patients with uncontrolled essential h... 2015-07-28 due-trials
Reported results 2012-001666-15 Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo given orally for 12 weeks in non depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, d... 2015-01-21 due-trials
Reported results 2012-001668-31 Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation, in patients with stable coronary artery disease. A 6 to 12-month ... 2014-04-14 due-trials
Reported results 2012-001689-13 Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation in patients with chronic heart failure and left ventricular systol... 2014-05-19 due-trials
Reported results 2012-001690-84 Safety and efficacy of fixed dose combination of Indapamide SR 1.5 mg / Amlodipine versus Valsartan / Amlodipine over 12-week of treatment with conditional titration based on the blood pressure contro... 2015-02-27 due-trials
Reported results 2012-002677-53 Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wall ... 2014-11-24 due-trials
Reported results 2012-002742-20 Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with Preserved left ventricular Ejection Fraction An 8-... 2016-02-29 due-trials
Reported results 2012-003404-12 Pharmacokinetics and safety of agomelatine in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with Depressive or Anxiety Disorder. An open-labelled, multicenter... 2015-03-14 due-trials
Reported results 2012-003559-13 Clinical non-inferiority study between Daflon 1000 mg, one oral suspension in a sachet per day and Daflon 500 mg, 2 tablets daily after eight weeks of treatment in patients suffering from symptomatic ... 2014-12-15 due-trials
Reported results 2012-003699-37 Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in no... 2015-02-11 due-trials
Reported results 2012-004779-38 Effects of ivabradine on plaque burden, morphology and composition in patients with clinically indicated coronary angiography. A randomised double-blind placebo-controlled international multicentre st... 2014-10-30 due-trials
Reported results 2012-005612-26 Efficacy and safety of tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomized, double-blind, flexible-dose, parallel groups... 2016-01-13 due-trials
Reported results 2012-005772-34 A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis or d... 2015-11-25 due-trials
Reported results 2013-000288-10 An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer. 2017-04-05 due-trials
Completed, but no date, and reported results 2013-002562-39 An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome. bad-data
Reported results 2013-002778-38 A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritis 2015-10-30 due-trials
Reported results 2013-003000-39 Evaluation of the pharmacodynamics, pharmacokinetics and safety of repeated escalating oral doses of S 38844 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunc... 2015-06-08 due-trials
Reported results 2013-003610-41 Dose-response study of gevokizumab (S 78989) 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD) Estudio dosis-respuesta de 3 mg, 10 mg, 30 mg ó 60 mg de gevo... 2015-10-28 due-trials
Reported results 2013-004973-29 A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study. 2015-11-02 due-trials
Reported results 2014-001519-38 Efficacy and safety of 3 doses of S 47445 versus placebo in patients with Alzheimer's disease at mild to moderate stages with depressive symptoms. A 24-week international, multi-centre, randomized, do... 2018-03-01 due-trials
Exempt, with results Terminated 2014-002251-26 Long-term safety study of abexinostat (S 078454) per os given as single-agent in haematological malignancies – Extension study 2015-02-24 not-yet-due
Reported results 2014-002333-63 A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in patients with paroxysmal atrial fibrillation Double-blind, International... 2016-09-06 due-trials
Reported results 2014-005378-12 Efficacy and Safety of Fixed-Dose Combination atorvastatin / amlodipine / perindopril versus Fixed-Dose Combination of atorvastatin / amlodipine in Patients with Hypertension and Dyslipidemia. Effi... 2016-09-08 due-trials
Listed as ongoing, but also has a completion date and reported results 2015-002181-23 Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with moderate to severe Major Depress... 2021-10-27 bad-data
Exempt, with results 2015-002646-31 Phase I/II study of oral administration of S 49076 given in combination with gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer who have progressed after treatment with EGFR t... 2018-11-07 not-yet-due
Reported results 2015-003867-13 Efficacy and safety of S 47445 versus placebo as adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to antidepressant therapy. A randomised, double-blind, placeb... 2017-04-06 due-trials
Exempt, with results 2015-004293-15 A phase 1, open label, non-comparative, study to evaluate the safety and the ability of UCART19 to induce molecular remission in paediatric patients with relapsed /refractory B acute lymphoblastic leu... 2020-11-04 not-yet-due
Reported results 2015-004544-18 An open-label, randomised, non-comparative phase 2 study evaluating S 95005 (TAS-102) plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated metastatic COlorectal can... 2020-09-01 due-trials
Exempt, with results 2016-000296-24 Phase I, open label, dose-escalation study to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor),... 2020-07-28 not-yet-due
Other 2016-000297-38 Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor) not-yet-due
Reported results 2016-001005-16 Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event. International, multi-centre, randomized, double-blind placebo-controlled phase II study. 2019-03-10 due-trials
Reported results 2016-002311-18 An open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer. 2020-11-30 due-trials
Ongoing 2016-004907-30 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects = 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with... not-yet-due
Reported results 2017-000292-83 Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil to Evaluate the Health-related Quality of Life in Patients with Metastatic Colorectal Cancer 2020-12-24 due-trials
Exempt, with results 2017-002459-27 Phase I/II trial of S 81694 administered intravenously in combination with paclitaxel to evaluate the safety, pharmacokinetic and efficacy in metastatic breast cancer 2020-06-08 not-yet-due
Reported results 2017-002760-41 Assessment of Active Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) plasma kinetics in Patients at acute stage of Ischemic Stroke: Prospective, Multicentre, Open, Non-randomised, Biomarker Study ... 2018-04-05 due-trials
Reported results 2017-003633-28 Clinical non-inferiority study between Micronized purified flavonoid fraction 1000 mg, one chewable tablet per day and Micronized Purified Flavonoid Fraction 500 mg, 2 tablets daily after eight weeks ... 2019-10-07 due-trials
Ongoing, reported early 2017-004059-22 An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patient... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2017-004419-38 Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo ... 2021-09-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2017-004420-30 Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled multice... 2021-10-26 bad-data
Reported results 2017-004581-10 Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with knee osteoarthritis. A 52-week international, multi-regional, multi-center, randomized, double-blind,... 2020-07-14 due-trials
Exempt, with results Terminated 2019-000998-23 A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity of S64315 in patients with locally advanced or metastatic breast cancer in combi... 2021-03-19 not-yet-due
Other 2019-002481-13 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation not-yet-due
Exempt 2019-003456-36 A first in human Phase 1/2 open-label, multicenter, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors not-yet-due
Listed as ongoing, but also has a completion date and reported results 2019-003514-14 A Multicentre, Randomized, Double-blind, Placebo-controlled Dose-finding Study of S62798 in Patients with Intermediate-High Risk Acute Pulmonary Embolism on heparin 2020-07-15 bad-data
Exempt, with results 2019-004896-38 Phase I/II, international, multicentre, open-label, non-randomised, non-comparative study evaluating the safety, tolerability and clinical activity of intravenously administered S64315, a selective Mc... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2020-001526-59 A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients. An international, multicentre, randomised, double-blind, placebo-controlled study 2023-05-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2020-001976-14 An open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal canc... 2023-09-12 bad-data
Exempt 2020-003061-19 Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multi-centre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl2 i... not-yet-due
Completed, reported early 2020-004891-16 Evaluation of the clinical efficacy and safety of perindopril 10 mg/indapamide 2.5 mg/amlodipine 5 or 10 mg/bisoprolol 5 mg in single-pill combination after 8 weeks of treatment versus the free combin... 2023-12-14 not-yet-due
Trial is outside EEC, and reported results 2020-004894-29 A multicentre, Phase II Randomized study, Open-label, with 2-arm Parallel Group, comparing the pharmacokinetics of the Liquid and the Lyophilized Formulations of pegaspargase (S95014) in Treatment of ... bad-data
Trial is outside EEC, and reported results 2020-004895-17 A multicentre, roll-over study to provide continued treatment with lyophilized pegaspargase (S95014) in Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) bad-data
Reported results 2021-003151-41 A randomised, open-label, multi-centre, two-arm Phase 3 study comparing futuximab/modotuximab in combination with trifluridine/tipiracil to trifluridine/tipiracil single agent with a Safety Lead-In pa... 2023-06-21 due-trials
Trial is outside EEC, and reported results 2022-002190-28 A Phase 2 Clinical Study of SHP674 in Patients with Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia bad-data